Lisa Maree Williams/Getty Images News AstraZeneca ( NASDAQ: AZN ) announced Tuesday that its FDA-approved breast cancer therapy, Truqap (capivasertib), did not reach its main goals in a Phase 3 trial as a first-line option in combination with chemotherapy. Citing results from its CAPItello-290 trial, the company said that Truqap with paclitaxel chemotherapy did not meet the dual primary endpoints versus paclitaxel plus placebo in those with triple-negative breast cancer. The global trial was designed to evaluate improvement in overall survival (OS) in the overall patient population and a subgroup of patients with specific genetic alterations as its dual primary endpoints.
The drug combination's tolerability profile was largely consistent with past results, and there were no new safety events. Truqap is also undergoing other late-stage trials in combination with established therapies for breast and prostate cancer. The Anglo-Swedish drugmaker markets Truqap with Otsuka Pharma ( OTCPK:OTSKF ) ( OTCPK:OTSKY ) as a late-line therapy for certain patients with breast cancer.
More on AstraZeneca AstraZeneca: The Price Upside Is Exhausted For Now (Rating Downgrade) AstraZeneca: Plotting A Bold Path To $80 Billion Revenues, I'm Pausing For Breath AstraZeneca: A Triple Shot Of Income, Growth, And Value AstraZeneca gets FDA okay for Imfinzi for endometrial cancer AstraZeneca's Farxiga approved for type 2 diabetes for children as young as 10.
